THE EFFECT OF POLYMORPHISM IN GLUTATHIONE S-TRANSFERASES ON THE DEVELOPING SECOND MALIGNANT NEOPLASMS AFTER LEUKEMIA TREATMENT IN CHILDHOOD

<p>Background. Survivors of childhood leukemia have an increased risk of developing second malignant neoplasms and specific treatment factors such as alkylating agents, topoisomerase inhibitors and radiation have been associated with their occurrence. Genetic polymorphism in drug-metabolizing...

Full description

Bibliographic Details
Main Authors: Janez Jazbec, Vita Dolžan, Maruša Debeljak, Richard Aplenc, Berta Jereb
Format: Article
Language:English
Published: Slovenian Medical Association 2004-12-01
Series:Zdravniški Vestnik
Subjects:
Online Access:http://vestnik.szd.si/index.php/ZdravVest/article/view/2416
Description
Summary:<p>Background. Survivors of childhood leukemia have an increased risk of developing second malignant neoplasms and specific treatment factors such as alkylating agents, topoisomerase inhibitors and radiation have been associated with their occurrence. Genetic polymorphism in drug-metabolizing enzymes may result in impared detoxification of chemotherapeutics and may lead to increased risk for cancer.</p><p>Methods. To test if polymorphism in glutathione S-transferases (GST) genes is associated with occurrence of secondary malignant neoplasms, we compared GSTM1, GSTT1 and GSTP1 genotypes among 16 patients treated for childhood leukemia in whom second neoplasm occurred and matched the control group.</p><p>Results. GSTM1 null genotype was found in 44% of patients with second neoplasms and in 50% in control group (p = 0.768), GSTT1 null genotype in 19% of cases and in 29% of controls (p = 0.729) and GSTP1 105 Ile/ile in 50% of cases and 37% of controls (p = 0.537). Differences in distribution of GST genotypes in patients with second neoplasms after childhood leukemia, compared to a matched control group of patients were not statistically significant.</p><p>Conclusions. In our study we were not able to show relation between GST genotype and occurrence of second neoplasms after the childhood acute leukemia.<br /><br /></p>
ISSN:1318-0347
1581-0224